Once-daily rabeprazole, levofloxacin, clarithromycin-MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study)

Helicobacter Jul 16, 2019

Auttajaroon J, et al. - In this prospective randomized pilot study, researchers assessed a once-daily dosing H. pylori eradication regimen. The compared a once-daily treatment regimen containing levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg) for 7 or 14 days. A full 100 participants were randomized. High eradication rate was achieved with once-daily 14-day rabeprazole-, levofloxacin-, clarithromycin-MR-, and bismuth-containing therapy— suggesting the high efficacy of triple therapies with a proton-pump inhibitor, bismuth, and clarithromycin-MR or levofloxacin for once-a-day tailored therapy or as empiric therapy for first-line regimen.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen